Organoids and 3D Biology Models

Introduction to Organoids

Organoids are self-organising three-dimensional tissue structures grown in extracellular matrix gels (typically Matrigel or synthetic equivalents) from either adult tissue-resident stem cells or pluripotent stem cells (embryonic or induced pluripotent—iPSCs), recapitulating key structural and functional features of their tissue of origin. The organoid concept was established by Hans Clevers' laboratory demonstrating that single Lgr5+ intestinal stem cells could self-organise into self-renewing crypt-villus structures (intestinal organoids) in Matrigel with defined growth factor cocktails (EGF, Noggin, R-spondin1) reproducing the intestinal architecture indefinitely in vitro. This breakthrough launched an explosion of organoid systems representing virtually every major organ—brain, liver, kidney, pancreas, lung, colon, prostate, endometrium, retina, and more.

The transformative power of organoids lies in their superiority over 2D cell lines for recapitulating organ-specific biology: organoids maintain tissue architecture ensuring correct cell polarity, cell-cell junctions, and organismal-relevant gene expression patterns lost in 2D culture; they contain multiple cell types in physiologically relevant proportions (unlike single-cell-type monolayer cultures); they can be expanded indefinitely enabling biobanking for personalised medicine; and patient-derived organoids preserve the patient's tumour or disease tissue genomic and molecular characteristics enabling personalised drug sensitivity testing. Cancer organoid biobanks from patients on chemotherapy predict clinical drug response better than cell lines—with correlations of 80+ percent between organoid drug sensitivity and clinical outcomes in colorectal, ovarian, and pancreatic cancers.

Brain Organoids

Cerebral Organoids

The Madeline Lancaster (then in Juergen Knoblich's laboratory) cerebral organoid system (2013) enabled the most revolutionary organoid platform—generating structurally complex brain-like structures from human iPSCs with cortical layer organisation, choroid plexus formation, and electrophysiological activity. Protocol: iPSC embryoid bodies in ultra-low attachment conditions form; wnt/BMP inhibitors specify neural identity; transfer to Matrigel droplets and spinner flasks enables rotational culture supporting vascularisation-independent oxygen/nutrient diffusion; self-organisation generates radially organised ventricular zones, cortical plate regions, and subcortical structures. Comparison of human versus chimpanzee cerebral organoids using species-specific iPSCs revealed cell cycle length differences in progenitors contributing to human cortical expansion. Microcephaly disease modelling in patient-derived organoids directly showed mitotic spindle defects in MCPH1-mutant cells explaining cortical volume loss.

Region-Specific Brain Organoids

Directed differentiation protocols using region-specific morphogenic signals generate organoids resembling specific brain regions: choroid plexus organoids (using high BMP4) produce CSF-like fluid and blood-CSF barrier function; hypothalamic organoids by canonical Wnt inhibition and Shh activation; midbrain organoids with floor plate specification generate dopaminergic neurons—used for Parkinson's disease patient iPSC modelling; thalamic, hippocampal, cerebellar, and spinal cord organoids have all been reported. Assembly organoids—brain region organoids fused together—enable modelling of region-region connectivity: fusion of ventral and dorsal forebrain organoids generates inhibitory interneuron migration recapitulating corticogenesis; striatal-cortical assembloids reveal corticostriatal circuit development and allow modelling of Huntington's disease excitotoxicity in human tissue.

Patient-Derived Tumour Organoids

Patient-derived tumour organoids can be established from tumour biopsies, surgical resections, or even circulating tumour cells—maintaining the genomic landscape, phenotypic diversity, and drug sensitivity of the patient's tumour better than established cell lines. Pancreatic ductal adenocarcinoma (PDAC)—historically lacking good preclinical models for a highly treatment-resistant cancer—can now be maintained as organoids from EUS-FNB (endoscopic ultrasound fine needle biopsies) guiding individualised therapy decisions. Brain tumour organoids from glioblastoma resections maintain intratumoural heterogeneity and immunosuppressive microenvironment features. Urothelial carcinoma organoids from cystoscopy biopsies enabled prospective chemotherapy response prediction in the TUMOROID clinical trial. The Manchester Organoid Registry and similar biobanks enable retrospective and prospective validation of organoid-based personalised medicine approaches at scale.

Organ-on-Chip Technology

Organs-on-chips combine microfluidic engineering with cell biology—growing cells in micro-scale chambers with precisely controlled shear stress, mechanical strain, and cell-cell interfaces not achievable in static organoids. Don Ingber's Wyss Institute lung-on-a-chip (PDMS microdevice with human lung airway epithelial and endothelial cells separated by an elastic membrane cyclically stretched to mimic breathing) reproduces pulmonary oedema induced by cancer drug IL-2 and rescue by angiopoietin-1—results later validated in human trials. Gut-on-chip, liver-on-chip, brain-on-chip, kidney-on-chip, and multi-organ systems (body-on-chip) better recapitulate in vivo ADMET (absorption, distribution, metabolism, excretion, toxicity) properties of drugs, serving as human surrogates for preclinical testing with potential to reduce animal use.

Examples and Applications

Example 1: Intestinal Organoid Drug Screening for IBD

Colonic organoids from IBD (Crohn's disease, ulcerative colitis) patients maintain patient-specific epithelial barrier functions, cytokine responsiveness, and microbiome susceptibility—enabling patient-specific drug testing. Colonoid monolayers on Transwell inserts enable barrier resistance (TEER) measurement and bacterial translocation assays; organoids challenged with IBD-related cytokines (TNF, IL-13, IFN-gamma) model mucosal inflammation. Patient organoid-based drug screening identified that organoids from patients responding to vedolizumab (anti-integrin alpha4beta7) showed specific immune cell-dependent barrier responses differentiating responders from non-responders. Drug sensitivity differences between Crohn's CD14hi and CD14lo macrophage subtypes modelled using macrophage-epithelial co-cultures in organoid format guide understanding of Crohn's subtype-specific treatment. Organoid-based microbiome colonisation experiments model the microbiome-epithelial crosstalk disrupted in IBD.

Example 2: Pancreatic Beta-Cell Organoids for Diabetes

Generating functional insulin-secreting beta cells from human iPSCs required understanding developmental pancreatic specification signals (definitive endoderm → primitive gut tube → posterior foregut → pancreatic progenitor → endocrine progenitor → beta cell), each stage driven by distinct morphogen cocktails (Activin/Wnt → Keratinocyte growth factor + KAAD-cyclopamine → Retinoic acid + ILV → Nicotinamide + Exendin-4). Vertex Pharmaceuticals' iPSC-derived islet (VX-880) programme transplanted stem cell-derived islet cells into type 1 diabetes patients through hepatic portal infusion—early data (2021-2023) showed insulin independence in multiple patients, the first functional cure of T1D from cell therapy. Because allogeneic iPSC-derived islets require immunosuppression, hypoimmunogenic (HLA-knockout + CD47/PD-L1 knock-in) iPSC lines enable transplantation without immunosuppression—tested preclinically and in Phase I clinical trials.

Example 3: Retinal Organoids in Gene Therapy Development

Human retinal organoids—generated from iPSCs using recapitulation of developmental signals (BMP4 for eyecup, FGF for neural retina, CHIR99021 for retinal pigment epithelium)—contain stratified photoreceptor layers with outer segment formation, functional light-sensitive cone and rod photoreceptors measurable by electrophysiology, Muller glia, ganglion cells, and bipolar cells. Patient iPSC-derived retinal organoids from retinitis pigmentosa (RP11, PRPF31; Usher syndrome, USH2A; LCA, CEP290 mutations) reproduced disease-specific photoreceptor degeneration and validated AAV gene therapy rescue—with AAV-RPGR rescuing photoreceptors in RPGR-RP retinal organoids predicting clinical trial outcomes. Antisense oligonucleotide splice-switching for intronic CEP290 mutation (Sepofarsen, EDIT-101) was validated in human organoid models before clinical trials.

Example 4: Liver Organoids and Hepatotoxicity

Hepatocyte-like organoids from liver ductal progenitors or iPSC differentiation are used to predict drug-induced liver injury (DILI)—the leading cause of post-approval drug withdrawal. 3D spheroid hepatocyte cultures maintain viability for 3-4 weeks (versus 48 hours for monolayer) and recover CYP3A4/CYP2D6/CYP1A2 activities approaching in vivo levels—critical for hepatotoxicity prediction requiring metabolic activation (troglitazone, diclofenac, fialuridine toxicity requires bioactivation). Liver-on-chip with flowing media enables chronic low-concentration DILI testing missed by acute high-dose assays. Patient-derived liver organoids from Wilson's disease patients with ATP7B mutations accumulate copper reproducibly, enabling evaluation of copper chelation and gene correction efficacy. Bile duct organoids from biliary atresia patients model the JAG1/Notch-mediated bile duct formation defect, enabling drug screens targeting ductal differentiation.

Example 5: Kidney Organoids

Kidney organoids established by Jamie Davies and Melissa Little contain nephrons with proximal tubule, distal tubule, loop of Henle, and glomerulus with podocytes and Bowman's space—although lacking collecting duct and interstitium. Podocyte architecture (podocin, nephrin, WT1 expression) recapitulates normal glomerular biology. Polycystic kidney disease (PKD, PKD1/PKD2 mutations) organoids develop massive fluid-filled cysts from proximal tubules, reproducing the PKD phenotype in vitro. mTOR inhibitors reduce organoid cyst formation—consistent with clinical ADPKD trial data. Nephrotoxicity testing in kidney organoids predicted cisplatin nephrotoxicity 3.2x better than 2D proximal tubular cells, improving the preclinical-clinical translation gap. Combining vascularised kidney organoids with endothelial tube formation enables modelling diabetic nephropathy glomerular hypertrophy and podocyte injury.

Example 6: Assembloid Models of Neural Disease

Brain region organoid assembloids—fusing separately produced dorsal forebrain, ventral forebrain, hypothalamic, and brainstem organoids—enable modelling of multi-region interactions in neural diseases. Sergiu Pasca's laboratory developed corticothalamic assembloids where thalamic interneurons migrate and synaptically integrate into cortical organoids, reproducing corticothalamic circuit development—defective in autism spectrum disorder and schizophrenia patient assembloids. Spinal cord-muscle assembloids model neuromuscular junction formation; ALS patient iPSC-derived spinal cord assembloids showed selective motor neuron axon retraction from muscle targets preceding death. Rett syndrome (MECP2 mutation) assembloids revealed specific impairment of inhibitory interneuron migration and integration into cortical circuits, identifying the circuit-level basis of altered inhibition/excitation balance in Rett syndrome.

Example 7: Tubuloidal Culture for Kidney Regeneration

Tubuloids from urine-derived cells or kidney biopsy material are organoid cultures enriched for proximal and distal tubular cell types—maintainable for years as self-renewing cultures. Key applications: biobank of tubuloids from PKD, nephronophthisis, renal tubular acidosis, and other tubular disorders for drug screening and disease mechanism research. Gene correction of PKD1 tubuloid organoids using CRISPR restored normal PKD1 expression and reduced cyst formation, modelling a potential gene therapy approach. Tubuloid transplantation into acutely injured or cisplatin-depleted mouse kidneys showed initial engraftment in peritubular locations—providing a potential cell therapy approach for acute kidney injury. Construction of bioartificial kidney tubular devices using tubuloid-seeded artificial tubular membranes is being developed as a complement to haemodialysis providing tubular resorptive functions currently lost in kidney failure patients on dialysis.

Example 8: COVID-19 Modelling in Organoids

SARS-CoV-2 pathophysiology was rapidly studied using multiple organoid systems after the pandemic onset. Choroid plexus organoids infected with SARS-CoV-2 revealed tropism for choroid plexus cells (high ACE2 expression) causing barrier disruption—potentially explaining CNS effects in COVID-19. Lung organoids, intestinal organoids, kidney organoids, and vascular organoids all showed productive SARS-CoV-2 infection recapitulating tropism based on ACE2/TMPRSS2 expression patterns. Brain organoids showed SARS-CoV-2 infection in cortical neurons with neuro-inflammatory responses and cell death even with relatively low viral load—modelling COVID-related neurological symptoms. Drug screening using infected organoids identified candidate antivirals (remdesivir confirmed active in multiple organoid systems; camostat/foipan TMPRSS2 inhibitors; monoclonal antibodies neutralising infection in airway organoids) before clinical trials, demonstrating organoids' value as pandemic drug discovery tools.

Try it live

Everything above runs in your browser — open Organoid Growth & Drug-Response Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.